Patients should be educated on recognising and treating hypoglycaemia promptly
![does semaglutide cause blurry vision Ozempic Loss Lawsuit [2026 Update] How Does Semaglutide Affect Eye](https://media.allaboutvision.com/cms/caas/v1/media/1348632/data/a6b7c26114b7611348a77eb693b5f0c4)
Human drug compounding, Food and Drug Administration (2024) Compounding when drugs are on FDAs drug shortages list, Food and Drug Administration (2024) FDA drug shortages: Semaglutide injection, Food and Drug Administration FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products, Food and Drug Administration (2024) FDAs concerns with unapproved GLP-1 drugs used for weight loss, Food and Drug Administration (2024) Ozempic, DailyMed (2024) Find out if your insurance covers Ozempic, Novo Nordisk FDA warns patients and health care professionals not to use compounded drugs from Fullerton Wellness, Food and Drug Administration (2024) Company statement: Novo Nordisk escalates legal actions to safeguard patients from potentially harmful compounded semaglutide drugs, Novo Nordisk (2024) FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize, Food and Drug Administration (2025) Medically accurate: SingleCares Medical Review Board analyzes all of our content to confirm its in line with current medical advice
![does semaglutide cause blurry vision Ozempic Loss Lawsuit [2026 Update] How Does Semaglutide Affect Eye](https://lookaside.instagram.com/seo/google_widget/crawler/?media_id=3421344757437450189)
Key details Treatments include compounded semaglutide in injection and oral tablet formats and compounded tirzepatide as an injection
The more meaningful caveat is that they are unapproved compounded products, so formulation and quality vary by pharmacy which makes your choice of compounder a clinical decision, not a purchasing one
4) Minimal Cost Impact: Even at $400,000/kg, the drug cost per dose is under $1, making the higher raw material cost acceptable in the broader economics of injectable drug products